Kuros Biosciences AG (KURN.SW)
CHF 28.4
(6.29%)
CHF 28.4
(6.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -13.19 Million CHF | 33.77% |
| 2022 | -13.44 Million CHF | -53.37% |
| 2021 | -8.76 Million CHF | 24.93% |
| 2020 | -11.67 Million CHF | -2.52% |
| 2019 | -11.39 Million CHF | 17.01% |
| 2018 | -13.72 Million CHF | 15.49% |
| 2017 | -16.24 Million CHF | 23.91% |
| 2016 | -21.34 Million CHF | -3363.91% |
| 2015 | 654 Thousand CHF | 103.45% |
| 2014 | -18.93 Million CHF | 18.61% |
| 2013 | -23.26 Million CHF | -72.4% |
| 2012 | -13.49 Million CHF | 31.55% |
| 2011 | -19.71 Million CHF | -410.2% |
| 2010 | -3.86 Million CHF | 85.81% |
| 2009 | -27.23 Million CHF | -14.05% |
| 2008 | -23.88 Million CHF | -187.75% |
| 2007 | -8.3 Million CHF | 76.35% |
| 2006 | -35.09 Million CHF | -19.7% |
| 2005 | -29.31 Million CHF | -21.26% |
| 2004 | -24.17 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -673 Thousand CHF | 0.0% |
| 2023 FY | -8.9 Million CHF | 33.77% |
| 2023 Q2 | -4.65 Million CHF | -105.7% |
| 2023 Q3 | -2.06 Million CHF | 55.69% |
| 2023 Q4 | -4.24 Million CHF | -105.77% |
| 2023 Q1 | -2.26 Million CHF | 70.63% |
| 2022 FY | -13.44 Million CHF | -53.37% |
| 2022 Q3 | -3.73 Million CHF | -49.5% |
| 2022 Q1 | -1.19 Million CHF | 83.94% |
| 2022 Q2 | -2.49 Million CHF | -109.83% |
| 2022 Q4 | -7.71 Million CHF | -106.56% |
| 2021 Q4 | -7.4 Million CHF | -102.46% |
| 2021 FY | -8.76 Million CHF | 24.93% |
| 2021 Q1 | -724.5 Thousand CHF | 86.82% |
| 2021 Q2 | -1.56 Million CHF | -116.29% |
| 2021 Q3 | -3.65 Million CHF | -133.5% |
| 2020 Q4 | -5.49 Million CHF | -102.95% |
| 2020 FY | -11.67 Million CHF | -2.52% |
| 2020 Q3 | -2.7 Million CHF | 58.28% |
| 2020 Q2 | -6.49 Million CHF | -103.83% |
| 2020 Q1 | -3.18 Million CHF | 48.06% |
| 2019 FY | -11.39 Million CHF | 17.01% |
| 2019 Q2 | -5.54 Million CHF | -106.79% |
| 2019 Q4 | -6.13 Million CHF | -103.25% |
| 2019 Q3 | -3.01 Million CHF | 45.54% |
| 2019 Q1 | -2.67 Million CHF | 32.52% |
| 2018 Q3 | -3.97 Million CHF | -37.2% |
| 2018 FY | -13.72 Million CHF | 15.49% |
| 2018 Q1 | -2.89 Million CHF | 37.85% |
| 2018 Q4 | -3.97 Million CHF | 0.0% |
| 2018 Q2 | -2.89 Million CHF | 0.0% |
| 2017 Q1 | -3.46 Million CHF | 6.87% |
| 2017 Q4 | -4.65 Million CHF | 0.0% |
| 2017 Q3 | -4.65 Million CHF | -34.32% |
| 2017 Q2 | -3.46 Million CHF | 0.0% |
| 2017 FY | -16.24 Million CHF | 23.91% |
| 2016 FY | -21.34 Million CHF | -3363.91% |
| 2016 Q3 | -3.72 Million CHF | 46.46% |
| 2016 Q4 | -3.72 Million CHF | 0.0% |
| 2016 Q1 | -6.95 Million CHF | -344.04% |
| 2016 Q2 | -6.95 Million CHF | 0.0% |
| 2015 Q2 | -545.5 Thousand CHF | 0.0% |
| 2015 Q1 | -545.5 Thousand CHF | 0.0% |
| 2015 FY | 654 Thousand CHF | 103.45% |
| 2015 Q3 | -1.56 Million CHF | -186.98% |
| 2015 Q4 | -1.56 Million CHF | 0.0% |
| 2014 FY | -18.93 Million CHF | 18.61% |
| 2013 Q3 | -5.77 Million CHF | 8.03% |
| 2013 Q4 | -7.48 Million CHF | -29.62% |
| 2013 Q2 | -6.28 Million CHF | -68.68% |
| 2013 Q1 | -3.72 Million CHF | -216.97% |
| 2013 FY | -23.26 Million CHF | -72.4% |
| 2012 FY | -13.49 Million CHF | 31.55% |
| 2012 Q4 | 3.18 Million CHF | 180.83% |
| 2012 Q3 | -3.93 Million CHF | -115.9% |
| 2012 Q1 | -2.73 Million CHF | 21.27% |
| 2012 Q2 | -1.82 Million CHF | 33.24% |
| 2011 Q1 | -4.93 Million CHF | 8.07% |
| 2011 Q3 | -6.97 Million CHF | -60.9% |
| 2011 Q4 | -3.47 Million CHF | 50.25% |
| 2011 FY | -19.71 Million CHF | -410.2% |
| 2011 Q2 | -4.33 Million CHF | 12.14% |
| 2010 FY | -3.86 Million CHF | 85.81% |
| 2010 Q4 | -5.36 Million CHF | 2.91% |
| 2010 Q3 | -5.52 Million CHF | -140.34% |
| 2010 Q2 | 13.7 Million CHF | 305.38% |
| 2010 Q1 | -6.67 Million CHF | -10.06% |
| 2009 Q2 | -5.1 Million CHF | 52.5% |
| 2009 FY | -27.23 Million CHF | -14.05% |
| 2009 Q4 | -6.06 Million CHF | -13.5% |
| 2009 Q3 | -5.34 Million CHF | -4.73% |
| 2009 Q1 | -10.73 Million CHF | 0.0% |
| 2008 FY | -23.88 Million CHF | -187.75% |
| 2007 FY | -8.3 Million CHF | 76.35% |
| 2006 FY | -35.09 Million CHF | -19.7% |
| 2005 FY | -29.31 Million CHF | -21.26% |
| 2004 FY | -24.17 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.31 Million CHF | -27.939% |
| BB Biotech AG | -29.92 Million CHF | 55.921% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | 168.69% |
| Evolva Holding SA | -92.24 Million CHF | 85.699% |
| Idorsia Ltd | -543.05 Million CHF | 97.571% |
| Molecular Partners AG | -61.1 Million CHF | 78.412% |
| Relief Therapeutics Holding AG | -110.82 Million CHF | 88.097% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 119.162% |